Takeda and Seattle Genetics are closing in on a new front-line use for their Adcetris in classical Hodgkin lymphoma after a successful late-stage trial. The positive results from the phase 3 ...

The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies ...

Adding Seagen's four approved oncology drugs – Adcetris (brentuximab vedotin) for blood cancers, Padcev (enfortumab vedotin) for bladder cancer and cervical cancer therapy Tivdak (tisotumab ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from an open-label extension of the Phase 3 ...

At close: May 30 at 4:00:02 PM EDT ...

Adcetris Improves Lymphoma Outcomes, Regardless of PET Scan Results Jordyn Sava September 11th 2023 While PET scans have been used to predict Hodgkin lymphoma outcomes, adding Adcetris to frontline ...

Poster session details are as follows: Date: Friday, May 12, 2023 Time: 12:15 – 1:00 p.m. CET/ 6:15 – 7:00 a.m. ET VERITAC update: phase 2 study of ARV-471, a PROteolysis TArgeting Chimera ...